Skip to main content
NCBI home page
Clinical Nutrition Research logoLink to Clinical Nutrition Research
. 2022 Jul 26;11(3):214–227. doi: 10.7762/cnr.2022.11.3.214

Anti-hypertensive Effects of Artichoke Supplementation in Adults: A Systematic Review and Dose-response Meta-analysis of Randomized Controlled Trials

Mohammad Reza Amini 1, Fatemeh Sheikhhossein 2, Mohsen Alvani 3, Seyyed Morteza Seyyed Shoura 4, Asma Sohrabnavi 4, Ehsan Heidarian 5, Azita Hekmatdoost 6,✉
PMCID: PMC9348915  PMID: 35949557

Abstract

Despite controversies, no earlier study has systematically summarized findings from earlier studies on the effect of artichoke supplementation on blood pressure. Therefore, current systematic review and meta-analysis was done on the effect of artichoke supplementation on systolic blood pressure (SBP) and diastolic blood pressure (DBP) in adults. Five databases were searched from inception to January 2022 using relevant keywords. All randomized clinical trials investigating the impact of oral artichoke supplementation on any of the blood pressure parameters including SBP or/and DBP were included. Out of 1,507 citations, 7 trials that enrolled 472 subjects were included. Artichoke supplementation resulted in significant reduction in SBP (weighted mean difference [WMD], −2.01 mmHg; 95% confidence interval [CI], −3.78, −0.24; p = 0.026) and DBP (WMD, −1.45 mmHg; 95% CI, −2.81, −0.08; p = 0.038). Greater effects on SBP were detected in trials using ≤ 500 mg artichoke, lasted > 8 weeks, participants aged < 50 years’ old and sample size ≤ 70. There was also a similar impact of artichoke on DBP. However, significant non-linear associations were found between artichoke supplementation dosage and study duration with both SBP (for dosage: pnon-linearity = 0.002, for duration: pnon-linearity = 0.016) and DBP (for dosage: pnon-linearity = 0.005, for duration: pnon-linearity = 0.003). We found a significant reduction in both SBP and DBP following artichoke supplementation in adults. It could be proposed as a hypotensive supplement in hypertension management.

Keywords: Artichoke, Hypertension, Blood pressure

INTRODUCTION

Hypertension (HTN) is an independent risk factor for cardiovascular disease. Constant increased pressure in blood vessels can silently damage the blood vessels, heart, brain, and kidneys [1,2]. The prevalence of HTN increased at an alarming rate between 1975 and 2015 among people aged 18 years and older [3]. HTN is also a lifestyle-related disease and lifestyle changes are effective for its management and prevention including reducing alcohol drinking; avoiding high sodium chloride intake; and consuming a diet loaded with fruits, vegetables, and low-fat dairy products with a reduced amount of saturated and total fat [1,2]. Recently adherence to the “DASH diet” which emphasizes consumption of fruit, and vegetables have emerged as an effective approach to reducing blood pressure [4]. Besides lifestyle modification, most patients will need antihypertensive drugs to confer multiple mechanisms suspected of having a role in their HTN [5]. Lowering systolic blood pressure (SBP) by 10–12 mmHg and diastolic blood pressure (DBP) by 5–6 mmHg contracts relative risk reductions of 35%–40% for stroke and 12%–16% for coronary heart disease within 5 years of initiating treatment [6]. As long-term use of medications could exert adverse effects comprising dizziness, dehydration, constipation, and drowsiness [7] adopting effective alternative therapies in particular dietary management, which could prevent future complications would be very valuable [8]. One of the therapeutic plants with a beneficial impact on HTN [9,10,11,12] is the Cynara scolymus L. (commonly known as artichoke). Lately, artichoke and its products have gained attention in scientific society. Artichoke is related to the traditional Mediterranean diet style, as is a well-known plant in the Mediterranean countries [13]. Artichoke’s leaves contain polyphenolic compounds, prebiotics (inulin), minerals, ascorbic acids, and folate [13]. Its leaf extract is rich in dietary fibers and antioxidant components [14], proposing the extract as beneficial in the control of HTN. Based on an experimental study, artichoke leaf extract also increases endothelial nitric oxide synthase (eNOS) gene expression and nitric oxide (NO) production in cultured human vascular endothelial cells and enhances endothelium-dependent vasodilation in mice aorta [15]. The current evidence is relatively limited and non-conclusive and only a few studies have reported that the supplementation of artichoke and artichoke products have a promising effect on controlling blood pressure [9,10,11,12]. While these findings are not supported by other studies [14,16,17]. A recent meta-analysis indicated that artichoke supplementation did not affect blood pressure. However, it appears that several studies included in that meta-analysis had included artichoke supplementation in combination with other interventions (co-supplementation) that have yielded different results from the present study. For instance, in the study of Cicero et al. [18] artichoke and berberis, and in the study of Ahn et al. [19] Jerusalem artichoke and fermented soybean powder mixture supplementation have been considered combination as an intervention. Also, 2 other articles are included in the present study [16,17]. Therefore, current systematic review and meta-analysis were conducted to summarize earlier controlled clinical trials assessing the effect of artichoke intake on blood pressure.

MATERIALS AND METHODS

The Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines were followed in conducting this systematic review and meta-analysis [20].

Search strategy

Online medical databases, including MEDLINE, Scopus, Cochrane Library, Embase, and Web of Science were searched from inception until January 2022. The search algorithm included all possible Medical Subject Headings (MeSH) and non-MeSH terms: (artichoke[tiab] OR artichokes[tiab] OR Cynara[tiab] OR "Cynara scolymus"[Mesh] OR Cynara[Mesh]) AND (hypertension[tiab] OR "Blood Pressure"[tiab] OR Prehypertension[tiab] OR BP[tiab] OR "Systolic blood pressure"[tiab] OR SBP[tiab] OR "Diastolic blood pressure"[tiab] OR DBP[tiab] OR cardiovascular[tiab] OR hypotensive[tiab] OR "Hypertension"[Mesh] OR "Blood Pressure"[Mesh] OR "Prehypertension"[Mesh]) AND (intervention[tiab] OR RCT[tiab] OR "controlled trial"[tiab] OR randomized[tiab] OR random[tiab] OR Randomly[tiab] OR Placebo[tiab] OR Assignment[tiab] OR "clinical trial"[tiab] OR trial[tiab] OR randomised[tiab] OR "Methods"[Mesh] OR "Randomized Controlled Trial"[Publication Type] OR "Controlled Clinical Trial"[Publication Type] OR "Placebos"[Mesh] OR "Placebo Effect"[Mesh] OR "Clinical Trial"[Publication Type] OR "Clinical Trials as Topic"[Mesh]). Moreover, to avoid missing any related studies, we manually searched the references of the included articles.

Inclusion and exclusion criteria

The search terms and strategies were constructed according to the PICOS model [21] including questions about participants (adults aged > 18 years), intervention (artichoke), comparator (placebo), outcome (SBP and DBP), and study design (parallel and cross-over clinical trial).

Studies were excluded if they were; letters, comments, conference papers, reviews, meta-analyses, and ecologic studies, if they were conducted on animals, or children, or were not placebo-controlled groups and assessed the effects of supplementation along with other interventions. Also, unpublished and grey literature, like patents, congress abstracts, and dissertations were excluded. In addition, we excluded publications examining the effects of artichoke supplementation in combination with other interventions (co-supplementation) [18,19]. We also excluded studies that did not include the placebo group [22].

Data extraction

Study selection and data extraction were performed at least twice by an independent researcher (FS). Any disagreement about eligibility was discussed with a second reviewer (MRA). The following data were collected from each study: study characteristics (first author’s name, year of publication, study location, publishing year, and study design), participant characteristics (mean age and sex of participants separately by intervention and non-intervention groups, the health status of the population, number of participants in each group) and intervention (type, dose, and duration of supplementation) and mean and standard deviation (SD) of obesity indices at baseline, and end of study or changes between baseline and post-intervention.

Quality assessment of studies

The quality of studies was assessed for risk of bias by using the Revised Cochrane risk-of-bias tool (RoB 2) [23]. The following methodological domains were considered: (1) random sequence generation, (2) allocation concealment, (3) blinding of participants and personnel, (4) blinding of outcome assessment, (5) incomplete outcome data, (6) selective reporting, and (7) other potential threats to validity. According to Cochrane Handbook recommendation, studies were stratified as low risk of bias; high risk of bias, and some concerns (Table 1).

Table 1. Risk of bias for randomized controlled trials, assessed according to the Revised Cochrane risk-of-bias tool for randomized trials (RoB 2).

Publications Randomization process Deviations from the intended interventions Missing outcome data Measurement of the outcome Selection of the reported result Overall bias
Roghani-Dehkordi et al. (2009) [10] L L L L L L
Rangboo et al. (2016) [9] L L S L L L
Panahi et al. (2018) [14] L L L L L L
Ebrahimi-Mameghani et al. (2018) [11] L L S L L L
Rezazadeh et al. (2019) [16] L L S L L L
Rondanelli et al. (2020) [17] L L L L L L
Ardalani et al. (2020) [12] L L L L L L
Open in a new tab

L, low risk of bias; S, some concerns.

Statistical analysis

We estimated the effect of artichoke on SBP and DBP by pooling mean and SD values of the baseline and the end of the studies in both intervention and control groups. If the studies did not report mean and SD, we converted the available statistical data into mean and SD by applying the suitable formula: SDdifference = Square Root [(SDpre-treatment)2 + (SDpost-treatment)2 − (2 × R × SDpre-treatment × SDpost-treatment)], assuming a correlation coefficient (R) 0.8 as it is a conservative estimate for an expected range of 0–1 [24]. When means (± SD) of outcome measures were not directly available and a standard error of the mean (SEM) was presented in place of SD, we converted it to SD using this formula: SD = SEM × √n, being “n” the number of subjects in each group. Ultimately, we used the GetData Graph Digitizer version 2.24 to extract data from studies that reported outcomes in the graphical form [25].

At first, a fixed-effect model was performed to determine the relationship with a forest plot. The degree of heterogeneity was defined based on I-squared statistic. The heterogeneity was substantially significant when the Cochrane’s test showed I2 greater than 50% with a p value < 0.1. Data with significant heterogeneity were analyzed using DerSimonian and Laird random-effects model, otherwise, a fixed-effect model was performed [26]. A priori subgroup analysis of intervention and duration of supplementation, sample size, dosage, and mean age was performed to detect potential sources of heterogeneity. We also performed fractional polynomial modeling to identify non-linear potential effects of artichoke dosage (mg/day) and duration of intervention (weeks) [27]. Any publication bias was investigated by visually inspecting funnel plots and quantitatively evaluated using Egger test [28]. Meta-analysis was carried out using Stata software, version 14.0 (Stata Corp LP, College Station, TX, USA). The p values less than 0.05 were regarded to be statistically significant.

RESULTS

Study selection

At first, 1,507 relevant articles were included at the initial stage, and an additional one articles were identified through hand-searching references of included papers. We identified 168 duplication records after removing duplicates, 1,340 relevant articles were screened by title and abstract, and after screening by title and abstract, unrelated studies were discarded due to the primary evaluation of inclusion criteria: unrelated title (n = 1,074), animal study (n = 135), and review (n = 114) and 17 papers were retained for full-text review. Of these articles, 10 were excluded because of the following reasons: irrelevant (n = 3), has no placebo-controlled group (n = 1), complex intervention (n = 1), without sufficient data for outcomes (n = 2), and conference abstracts (n = 3). Finally, 7 studies met all our inclusion criteria [9,10,11,12,14,16,17]. Figure 1 demonstrates the process by which articles were selected.

Figure 1. Flow chart of the number of studies identified and selected into the meta-analysis.

Figure 1

Open in a new tab

Study characteristics

The summary of the main features of the included studies is shown in Table 2. We identified 7 randomized clinical trials that assessed the effects of artichoke on SBP and DBP [9,10,11,12,14,16,17]. Selected eligible trials enrolled 472 participants with ages ranging from 38.4 to 51.5 years old [16,17]. These studies were carried out in various countries including Iran [9,10,11,12,14,16], and Italy [17]. Participant health status was as follows: non or mild hypercholesterolemia [9,10], hypertriglyceridemia [16], non-alcoholic fatty liver disease [14], metabolic syndrome [11], overweight and obese with newly detected impaired fasting glucose [17], and hypertensive [12]. Most of the studies recruited both sexes [9,11,12,14,16,17], however some studies were conducted in males [10]. Seven papers analyzed the effectiveness of interventions on both SBP and DBP [9,10,11,12,14,16,17]. Seven studies had parallel designs [9,10,11,12,14,16,17]. The artichoke was administrated in doses ranging from 50 mg/day [10] and 2,700 mg/day [9]. The shortest intervention period was 4 weeks [17] and the longest one was 12 weeks [10,11,16]. The sample size was different from 40 participants [12] to 89 participants [14]. Baseline body mass index was various from 24.5 kg/m2 [10] to 34.3 kg/m2 [11].

Table 2. Demographic characteristics of the included studies.

First author (yr) Location Study design Health status Sex Sample size Duration (wk) Mean age (yr) Baseline BMI (kg/m2) Intervention Outcome
Treatment group Control group
Roghani-Dehkordi et al. (2009) [10] Iran Randomized, double-blind, placebo-controlled, parallel trial Non or mild hypercholesterolemic Male 56 12 42.5 24.5 50 mg artichoke leaf extract Placebo SBP/DBP
Roghani-Dehkordi et al. (2009) [10] Iran Randomized, double-blind, placebo-controlled, parallel trial Non or mild hypercholesterolemic Male 51 12 42.5 24.5 100 mg artichoke leaf extract Placebo SBP/DBP
Rangboo et al. (2016) [9] Iran Randomized, double-blind, placebo-controlled, parallel trial Non or mild hypercholesterolemic NASH patients Both 66 8 48.9 NA 2,700 mg artichoke leaf extract Placebo SBP/DBP
Panahi et al. (2018) [14] Iran Randomized, double-blind, placebo-controlled, parallel trial Patients with NAFLD Both 89 8 46.2 29.1 600 mg artichoke leaf extract Placebo SBP/DBP
Ebrahimi-Mameghani et al. (2018) [11] Iran Randomized, double-blind, placebo-controlled, parallel trial Metabolic syndrome Both 68 12 38.9 34.3 1,800 mg artichoke leaf extract Placebo SBP/DBP
Rezazadeh et al. (2019) [16] Iran Randomized, double-blind, placebo-controlled, parallel trial Hypertriglyceridemia Both 48 12 38.4 33.8 1,800 mg artichoke leaf extract Placebo SBP/DBP
Rondanelli et al. (2020) [17] Italy Randomized, double-blind, placebo-controlled, parallel trial Overweight and obese with newly detected IFG Both 54 4 51.5 30.0 500 mg artichoke leaf extract Placebo SBP/DBP
Ardalani et al. (2020) [12] Iran Randomized, double-blind, placebo-controlled, parallel trial Hypertensive Both 40 8 45.0 29.5 1,000 mg artichoke leaf extract Placebo SBP/DBP
Open in a new tab

BMI, body mass index; NASH, nonalcoholic steatohepatitis; NAFLD, non-alcoholic fatty liver disease; IFG, impaired fasting glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; NA, not reported.

Effect of artichoke on SBP

Seven eligible trials including a total of 505 participants, examined the effect of artichoke supplementation on SBP. Combining their findings based on random-effects model, we found that SBP was significantly reduced in artichoke group compared to the control (weighted mean difference [WMD], −2.01 mmHg; 95% confidence interval [CI], −3.78, −0.24; p = 0.026), including a significant heterogeneity between studies (I2= 93.1%; P < 0.001) (Figure 2).

Figure 2. Forest plot detailing WMDs and 95% CIs for the effect of artichoke supplementation on systolic blood pressure.

Figure 2

Open in a new tab

WMD, weighted mean difference; CI, confidence interval.

Effect of artichoke on DBP

Seven qualified studies including a total of 505 subjects, reported DBP as their outcome. After pooling these studies based on random-effects model, we found a significant reduction in DBP following artichoke consumption (WMD, −1.45 mmHg; 95% CI, −2.81, −0.08; p = 0.038), with a significant between-study heterogeneity (I2= 90.3%; p < 0.001) (Figure 3).

Figure 3. Forest plot detailing WMD and 95% CIs for the effect of artichoke supplementation on DBP.

Figure 3

Open in a new tab

WMD, weighted mean difference; CI, confidence interval; DBP, diastolic blood pressure.

Subgroup analysis

Findings from the subgroup analyses are outlined in Table 3. After categorizing studies on the basis of artichoke dosage, SBP was significantly decreased for ≤ 500 mg (WMD, −3.00 mmHg; 95% CI, −3.54, −2.46; p < 0.001). The subgroup analyses based on duration of intervention revealed that the effect of artichoke supplementation on SBP was significantly greater in trials lasted > 8 weeks (WMD, −3.11 mmHg; 95% CI, −3.66, −2.56; p < 0.001) than ≤ 8 weeks (WMD, 0.21 mmHg; 95% CI, −0.18, 0.60; p = 0.281). Moreover, reduction in SBP after artichoke intake was remarkable in subjects aged < 50 years’ old (WMD, −3.08 mmHg; 95% CI, −3.62, −2.54; p < 0.001), but not in the elders (WMD, 0.23 mmHg; 95% CI, −0.17, 0.62; p = 0.258) and sample size ≤70 significantly changed SBP (WMD, −2.97; 95% CI, −3.65, −2.28; p < 0.001).

Table 3. Subgroup analysis of included randomized controlled trials in meta-analysis of the effect of artichoke supplementation on blood pressure.

Group No. of trials WMD (95% CI) p value I2 (%) p-heterogeneity p for between subgroup heterogeneity
SBP
Dosage (mg) < 0.001
≤ 500 2 −3.00 (−3.54, −2.46) < 0.001 50.8 0.131
> 500 5 0.20 (−0.19, 0.59) 0.321 56.0 0.059
Duration (wk) < 0.001
≤ 8 4 0.21 (−0.18, 0.60) 0.281 52.6 0.097
> 8 3 −3.11 (−3.66, −2.56) < 0.001 0.0 0.822
Mean age (yr) < 0.001
< 50 4 −3.08 (−3.62, −2.54) < 0.001 0.0 0.810
≥ 50 3 0.23 (−0.17, 0.62) 0.258 66.1 0.052
Sample size < 0.001
≤ 70 6 −2.97 (−3.65, −2.28) < 0.001 13.0 0.331
> 70 2 −0.34 (−0.69, 0.02) 0.067 98.0 < 0.001
DBP
Dosage (mg) 0.003
≤ 500 2 −2.37 (−2.94, −1.80) < 0.001 63.7 0.063
> 500 5 0.19 (−0.13, 0.51) 0.249 52.2 0.079
Duration (wk) 0.003
≤ 8 5 0.24 (−0.08, 0.57) 0.138 0.0 0.425
> 8 3 −2.53 (−3.10, −1.96) < 0.001 0.0 0.823
Mean age (yr) 0.003
< 50 4 −2.42 (−2.89, −1.86) < 0.001 0.0 0.567
≥ 50 3 0.25 (−0.07, 0.58) 0.128 40.7 0.185
Sample size 0.003
≤ 70 6 −2.20 (−2.91, −1.49) < 0.001 30.5 0.206
> 70 2 −0.10 (−0.40, 0.21) 0.538 97.3 < 0.001
Open in a new tab

SBP, systolic blood pressure; DBP, diastolic blood pressure; WMD, weight mean difference; CI, confidence interval.

DBP was also reduced by using lower doses (WMD, −2.37 mmHg; 95% CI, −2.94, −1.80; p < 0.001), but not in higher ones (WMD, 0.19 mmHg; 95% CI, −0.13, 0.51; p = 0.249). The subgroup analyses based on duration of intervention revealed that the effect of artichoke supplementation on DBP was significantly greater in trials lasted > 8 weeks (WMD, −2.53 mmHg; 95% CI, −3.10, −1.96; p < 0.001). Moreover, reduction in DBP after artichoke intake was remarkable in subjects aged < 50 years’ old (WMD, −2.42 mmHg; 95% CI, −2.89, −1.86; p < 0.001), and sample size ≤ 70 significantly changed DBP (WMD, −2.20; 95% CI, −2.91, −1.49; p < 0.001).

Non-linear dose-response relation between doses and duration of artichoke intake and outcomes

Following dose-response assessment, significant non-linear association between artichoke dosage and SBP (pnon-linearity = 0.002), and DBP (pnon-linearity = 0.005) was seen (Figure 4). Moreover, the duration of artichoke treatment showed significant non-linear association with SBP (pnon-linearity = 0.016), and DBP (pnon-linearity = 0.003) (Figure 5).

Figure 4. Non-linear dose-response relations between artichoke dosage (mg/day) and unstandardized mean difference in (A) SBP, and (B) DBP. The 95% CI is revealed in the shaded regions.

Figure 4

Open in a new tab

CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Figure 5. Non-linear dose-response relations between duration of treatment (weeks) and unstandardized mean difference in (A) SBP, and (B) DBP. The 95% CI is revealed in the shaded regions.

Figure 5

Open in a new tab

CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Sensitivity analysis

To explore the impact of every single trial on the pooled effect size, we removed each study from the analysis. Sensitivity analysis for SBP and DBP indicated that the overall estimates were influenced by the elimination of none of the included studies.

Publication bias

Egger’s weighted regression tests were conducted to find the publication bias. The results of Egger’s test showed no publication bias for SBP (p = 0.320) and DBP (p = 0.162).

DISCUSSION

This systematic review and dose-response meta-analysis of 7 clinical trials assessed available evidence about the blood pressure-lowering effect of artichoke supplementation in adults. The pooled results revealed a significant effect of artichoke in lowering SBP and DBP when compared with placebo/control. The subgroup analyses showed that SBP was reduced following artichoke supplementation in trials lasted > 8 weeks, in lower doses (500 mg or less), and subjects aged < 50 years old. There was also a similar impact of artichoke on DBP.

Over recent years, functional foods and nutraceuticals have gained attention due to their potential therapeutic effects on preventing cardiovascular risk factors [29]. Nutraceuticals, a food or part of a food that have medical or therapeutic benefits, are proposed as factors in the management of chronic diseases, glycemic and lipid metabolic disorders, and component of metabolic syndrome [30,31]. Preceding meta-analysis showed that artichoke supplementation was associated with a significant reduction in both total and low-density lipoprotein cholesterol, without an effect on either triglycerides or high-density lipoprotein cholesterol levels [32]. In addition, other systematic reviews evaluating the effect of artichoke supplementation on anthropometric and glycemic indices showed the promising effect of artichoke extract on fasting blood glucose and waist circumference but without any effects on other factors [33,34]. To our knowledge, this systematic review and meta-analysis evaluated the effect of artichoke supplementation on blood pressure for the first time. In a study conducted by Roghani-Dehkordi et al. [10] either 50 mg/day or 100 mg/day artichoke for 12 weeks lowered DBP along with SBP through a dose-dependent pattern in patients with mild HTN. Also, artichoke supplementation (2,700 mg/day) for 2 months reduced SBP but did not affect DBP [9]. Findings from a study by Ebrahimi-Mameghani et al. [11] revealed that a 12-week supplementation with 1,800 mg/day artichoke did significantly affect either DBP or SBP in metabolic syndrome patients. However, another study showed that 2 months of artichoke supplementation with a dose of 600 mg/day increased SBP, while DBP did not differ between groups [14]. Moreover, it has been shown that 1,000 mg/day of artichoke had a beneficial effect on DBP but it did not affect SBP [12]. Additionally, taking 1,000 mg/day of artichoke for 8 weeks by obese and overweight patients was not associated with a significant change in SBP and DBP [17]. Different study designs, different baseline values of dependent variables, different doses of artichoke used along with characteristics of study participants might elucidate the discrepancies among included studies. In addition to human-based study, in vitro as well as experimental animals in vivo have shown a beneficial effect of artichoke on epithelial cells through its antioxidant’s effects [35,36]. The biologically active compounds of the artichoke such as phenolic acids (benzoic, ellagic, and caffeic), sesquiterpenes lactones (cynaropicrin), luteolin, phytosterols (β sitosterol, stigmasterol), and dietary fibers (inulin-type fructans) could contribute to a variety of biological functions, including lipid-lowering [37], hepatoprotective [38] and reducing oxidative stress [39]. Artichoke exerts its antihypertensive effects on leaf extracts through upregulation of eNOS expression and increased NO production which enhances endothelium-dependent vasodilation [15,40]. Additionally, it has been shown that some compounds of artichoke such as cynarin might prevent the development of atherosclerotic plaques [41], taken together, this evidence emphasizes the key role of artichoke supplementation in reducing blood pressure. According to human and animal studies, physiological and pharmacological doses of artichoke supplementation in wide ranges did not show any side effects, and there is extensive consonance regarding its nontoxicity [42]. Therefore, due to the fact that artichoke is affordable and can be easily produced in purely pharmacological form and notably, because of its protective effect on heart damage mutilation of vital molecules by free radicals via its antioxidant effect [41], and vasodilation through increasing NO production [15], it could be considered as a preventive treatment for cardiovascular disorders.

Our systematic review and meta-analysis has several strengths. Our search strategy was very precise and covered multiple databases. Statistical examinations showed no evidence of publication bias in our analyses. Nevertheless, this study had several weaknesses, and the findings should be interpreted with caution. Randomized controlled trials (RCTs) included in our meta-analysis were represented with various health conditions and study durations, which might potentially affect the results. However, all included patients in our meta-analysis had different kind of metabolic disorders and desired outcome was blood pressure. The existence of uncontrollable factors in the 2 comparison groups, such as eating habits and lifestyle, can effect the pooled results. Considering the limitations, further studies are needed to test the effect of artichoke on stress blood pressure.

In conclusion, this meta-analysis of available RCTs suggests a significant benefit of artichoke extract supplementation in decreasing blood pressure. Hence, additional clinical studies with a large sample size, duration, dosage, and route of administration (bio-availability) among people with mild HTN are needed to be done for a better understanding of the results obtained in this current meta-analysis.

ACKNOWLEDGEMENTS

This study is related to project No. 1400/65017 from Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

We also appreciate the “Student Research Committee” and “Research & Technology Chancellor” in Shahid Beheshti University of Medical Sciences for their financial support of this study.

Footnotes

Funding: This study is supported by “Student Research Committee” and “Research & Technology Chancellor” in Shahid Beheshti University of Medical Sciences.

Conflict of Interest: The authors declare that they have no competing interests.

Author Contributions:
  • Conceptualization: Amini MR.
  • Data curation: Amini MR.
  • Formal analysis: Amini MR.
  • Methodology: Sheikhhossein F.
  • Project administration: Hekmatdoost A.
  • Supervision: Hekmatdoost A.
  • Writing - original draft: Alvani M, Heidarian E, Sohrabnavi S.
  • Writing - review & editing: Sheikhhossein F, Seyyed Shoura SM.

References

  • 1.Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Arch Intern Med. 2004;164:2126–2134. doi: 10.1001/archinte.164.19.2126. [DOI] [PubMed] [Google Scholar]
  • 2.Domanski M, Mitchell G, Pfeffer M, Neaton JD, Norman J, Svendsen K, Grimm R, Cohen J, Stamler J MRFIT Research Group. Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT) JAMA. 2002;287:2677–2683. doi: 10.1001/jama.287.20.2677. [DOI] [PubMed] [Google Scholar]
  • 3.NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet. 2017;389:37–55. doi: 10.1016/S0140-6736(16)31919-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM American Heart Association. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension. 2006;47:296–308. doi: 10.1161/01.HYP.0000202568.01167.B6. [DOI] [PubMed] [Google Scholar]
  • 5.Schiffrin EL. Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertens. 2004;17:1192–1200. doi: 10.1016/j.amjhyper.2004.05.023. [DOI] [PubMed] [Google Scholar]
  • 6.Lammers AE. Predicting prognosis of children with pulmonary arterial hypertension: the importance of multimodal expert assessment. Heart. 2014;100:1305–1307. doi: 10.1136/heartjnl-2014-306010. [DOI] [PubMed] [Google Scholar]
  • 7.Husserl FE, Messerli FH. Adverse effects of antihypertensive drugs. Drugs. 1981;22:188–210. doi: 10.2165/00003495-198122030-00002. [DOI] [PubMed] [Google Scholar]
  • 8.Ardalani H, Moghadam M, Rahimi R, Soltani J, Mozayanimonfared A, Moradi M, Azizi A. Sumac as a novel adjunctive treatment in hypertension: a randomized, double-blind, placebo-controlled clinical trial. RSC Adv. 2016;6:11507–11512. [Google Scholar]
  • 9.Rangboo V, Noroozi M, Zavoshy R, Rezadoost SA, Mohammadpoorasl A. The effect of artichoke leaf extract on alanine aminotransferase and aspartate aminotransferase in the patients with nonalcoholic steatohepatitis. Int J Hepatol. 2016;2016:4030476. doi: 10.1155/2016/4030476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Roghani-Dehkordi F, Kamkhah AF. Artichoke leaf juice contains antihypertensive effect in patients with mild hypertension. J Diet Suppl. 2009;6:328–341. doi: 10.3109/19390210903280207. [DOI] [PubMed] [Google Scholar]
  • 11.Ebrahimi-Mameghani M, Asghari-Jafarabadi M, Rezazadeh K. TCF7L2-rs7903146 polymorphism modulates the effect of artichoke leaf extract supplementation on insulin resistance in metabolic syndrome: a randomized, double-blind, placebo-controlled trial. J Integr Med. 2018;16:329–334. doi: 10.1016/j.joim.2018.05.006. [DOI] [PubMed] [Google Scholar]
  • 12.Ardalani H, Jandaghi P, Meraji A, Hassanpour Moghadam M. The effect of Cynara scolymus on blood pressure and BMI in hypertensive patients: a randomized, double-blind, placebo-controlled, clinical trial. Complement Med Res. 2020;27:40–46. doi: 10.1159/000502280. [DOI] [PubMed] [Google Scholar]
  • 13.Ceccarelli N, Curadi M, Picciarelli P, Martelloni L, Sbrana C, Giovannetti M. Globe artichoke as a functional food. Med J Nutrition Metab. 2010;3:197–201. [Google Scholar]
  • 14.Panahi Y, Kianpour P, Mohtashami R, Atkin SL, Butler AE, Jafari R, Badeli R, Sahebkar A. Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: a pilot double-blind randomized controlled trial. Phytother Res. 2018;32:1382–1387. doi: 10.1002/ptr.6073. [DOI] [PubMed] [Google Scholar]
  • 15.Li H, Xia N, Brausch I, Yao Y, Förstermann U. Flavonoids from artichoke (Cynara scolymus L.) up-regulate endothelial-type nitric-oxide synthase gene expression in human endothelial cells. J Pharmacol Exp Ther. 2004;310:926–932. doi: 10.1124/jpet.104.066639. [DOI] [PubMed] [Google Scholar]
  • 16.Rezazadeh K, Asghari-Jafarabadi M, Ebrahimi-Mameghani M. The interaction of FTO-rs9939609 polymorphism with artichoke leaf extract effects on cardiometabolic risk factors in hypertriglyceridemia: a randomized clinical trial. Adv Intern Med. 2019;6:104–109. [Google Scholar]
  • 17.Rondanelli M, Riva A, Petrangolini G, Allegrini P, Bernardinelli L, Fazia T, Peroni G, Gasparri C, Nichetti M, Faliva MA, Naso M, Perna S. The metabolic effects of Cynara supplementation in overweight and obese class I subjects with newly detected impaired fasting glycemia: a double-blind, placebo-controlled, randomized clinical trial. Nutrients. 2020;12:3298. doi: 10.3390/nu12113298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Cicero AF, Fogacci F, Bove M, Giovannini M, Veronesi M, Borghi C. Short-term effects of dry extracts of artichokeand berberis in hypercholesterolemic patients without cardiovascular disease. Am J Cardiol. 2019;123:588–591. doi: 10.1016/j.amjcard.2018.11.018. [DOI] [PubMed] [Google Scholar]
  • 19.Ahn HY, Kim M, Seo CR, Yoo HJ, Lee SH, Lee JH. The effects of Jerusalem artichoke and fermented soybean powder mixture supplementation on blood glucose and oxidative stress in subjects with prediabetes or newly diagnosed type 2 diabetes. Nutr Diabetes. 2018;8:42. doi: 10.1038/s41387-018-0052-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1. doi: 10.1186/2046-4053-4-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995;123:A12–A13. [PubMed] [Google Scholar]
  • 22.Talebi Pour B, Jameshorani M, Salmani R, Chiti H. The effect of Chlorella vulgaris vs. Artichoke on patients with non-alcoholic fatty liver disease (NAFLD): a randomized clinical trial. J Adv Med Biomed Res. 2015;23:36–44. [Google Scholar]
  • 23.Higgins JPT, Altman DG. In: Cochrane handbook for systematic reviews of interventions: Cochrane book series. Higgins JPT, Green S, editors. Hoboken: John Wiley & Sons; 2008. Assessing risk of bias in included studies; pp. 187–241. [Google Scholar]
  • 24.Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis. Hoboken: John Wiley & Sons; 2011. [Google Scholar]
  • 25.Fedorov S. GetData Graph Digitizer version 2.24 [Internet] 2002. [cited 2022 June 1]. Available from www.getdata-graph-digitizer.com.
  • 26.DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28:105–114. doi: 10.1016/j.cct.2006.04.004. [DOI] [PubMed] [Google Scholar]
  • 27.Fan J, Gijbels I. Local polynomial modelling and its applications: monographs on statistics and applied probability 66. London: Routledge; 2018. [Google Scholar]
  • 28.Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634. doi: 10.1136/bmj.315.7109.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Sosnowska B, Penson P, Banach M. The role of nutraceuticals in the prevention of cardiovascular disease. Cardiovasc Diagn Ther. 2017;7:S21–S31. doi: 10.21037/cdt.2017.03.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Cicero AF, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, Fras Z, Katsiki N, Langlois M, Latkovskis G, Panagiotakos DB, Paragh G, Mikhailidis DP, Mitchenko O, Paulweber B, Pella D, Pitsavos C, Reiner Ž, Ray KK, Rizzo M, Sahebkar A, Serban MC, Sperling LS, Toth PP, Vinereanu D, Vrablík M, Wong ND, Banach M. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Arch Med Sci. 2017;13:965–1005. doi: 10.5114/aoms.2017.69326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Patti AM, Al-Rasadi K, Giglio RV, Nikolic D, Mannina C, Castellino G, Chianetta R, Banach M, Cicero AF, Lippi G, Montalto G, Rizzo M, Toth PP. Natural approaches in metabolic syndrome management. Arch Med Sci. 2018;14:422–441. doi: 10.5114/aoms.2017.68717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Sahebkar A, Pirro M, Banach M, Mikhailidis DP, Atkin SL, Cicero AF. Lipid-lowering activity of artichoke extracts: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2018;58:2549–2556. doi: 10.1080/10408398.2017.1332572. [DOI] [PubMed] [Google Scholar]
  • 33.Hemati N, Venkatakrishnan K, Yarmohammadi S, Moradi M, Moravejolahkami AR, Hadi A, Moradi S, Aneva IY, Farzaei MH. The effects of supplementation with Cynara scolymus L. on anthropometric indices: a systematic review and dose-response meta-analysis of clinical trials. Complement Ther Med. 2021;56:102612. doi: 10.1016/j.ctim.2020.102612. [DOI] [PubMed] [Google Scholar]
  • 34.Jalili C, Moradi S, Babaei A, Boozari B, Asbaghi O, Lazaridi AV, Hojjati Kermani MA, Miraghajani M. Effects of Cynara scolymus L. on glycemic indices: a systematic review and meta-analysis of randomized clinical trials. Complement Ther Med. 2020;52:102496. doi: 10.1016/j.ctim.2020.102496. [DOI] [PubMed] [Google Scholar]
  • 35.Jiménez-Escrig A, Dragsted LO, Daneshvar B, Pulido R, Saura-Calixto F. In vitro antioxidant activities of edible artichoke (Cynara scolymus L.) and effect on biomarkers of antioxidants in rats. J Agric Food Chem. 2003;51:5540–5545. doi: 10.1021/jf030047e. [DOI] [PubMed] [Google Scholar]
  • 36.Magielse J, Verlaet A, Breynaert A, Keenoy BM, Apers S, Pieters L, Hermans N. Investigation of the in vivo antioxidative activity of Cynara scolymus (artichoke) leaf extract in the streptozotocin-induced diabetic rat. Mol Nutr Food Res. 2014;58:211–215. doi: 10.1002/mnfr.201300282. [DOI] [PubMed] [Google Scholar]
  • 37.Villanueva-Suárez MJ, Mateos-Aparicio I, Pérez-Cózar ML, Yokoyama W, Redondo-Cuenca A. Hypolipidemic effects of dietary fibre from an artichoke by-product in Syrian hamsters. J Funct Foods. 2019;56:156–162. [Google Scholar]
  • 38.Speroni E, Cervellati R, Govoni P, Guizzardi S, Renzulli C, Guerra MC. Efficacy of different Cynara scolymus preparations on liver complaints. J Ethnopharmacol. 2003;86:203–211. doi: 10.1016/s0378-8741(03)00076-x. [DOI] [PubMed] [Google Scholar]
  • 39.Küskü-Kiraz Z, Mehmetçik G, Doǧru-Abbasoǧlu S, Uysal M. Artichoke leaf extract reduces oxidative stress and lipoprotein dyshomeostasis in rats fed on high cholesterol diet. Phytother Res. 2010;24:565–570. doi: 10.1002/ptr.2985. [DOI] [PubMed] [Google Scholar]
  • 40.Rodriguez-Pascual F, Hausding M, Ihrig-Biedert I, Furneaux H, Levy AP, Förstermann U, Kleinert H. Complex contribution of the 3′-untranslated region to the expressional regulation of the human inducible nitric-oxide synthase gene. Involvement of the RNA-binding protein HuR. J Biol Chem. 2000;275:26040–26049. doi: 10.1074/jbc.M910460199. [DOI] [PubMed] [Google Scholar]
  • 41.Petrowicz O, Gebhardt R, Donner M, Schwandt P, Kraft K. Effects of artichoke leaf extract (ALE) on lipoprotein metabolism in vitro and in vivo. Atherosclerosis. 1997;1:147. [Google Scholar]
  • 42.Joy JF, Haber SL. Clinical uses of artichoke leaf extract. Am J Health Syst Pharm. 2007;64:1904, 1906–1909. doi: 10.2146/ajhp070013. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Nutrition Research are provided here courtesy of Korean Society of Clinical Nutrition

RESOURCES